Home> Products> glucose uptake

{ "products": [ { "_id": "68d51d9a26579f4bc195771a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg ", "description": "GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control.\n\nIt is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes.\n\n \n\nMechanism of Action\nThe therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism:\n\n1. Glimepiride (1 mg) – Sulfonylurea\nStimulates insulin secretion by activating pancreatic beta cells.\n\nProvides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas.\n\nHelps reduce both fasting and postprandial glucose levels.\n\n2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor\nDelays the breakdown and absorption of carbohydrates in the intestine.\n\nMinimizes post-meal glucose spikes (PPBG).\n\nActs locally in the gut and has minimal systemic absorption, which reduces systemic side effects.\n\n3. Metformin Hydrochloride SR (500 mg) – Biguanide\nDecreases hepatic glucose production (gluconeogenesis).\n\nImproves peripheral insulin sensitivity, enhancing glucose uptake in muscles.\n\nDoes not cause hypoglycemia on its own.\n\nThe sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects.\n\n \n\nIndications\nGLIMITERIS MV1 0.2 is indicated for:\n\nAdults with Type 2 Diabetes Mellitus.\n\nPatients inadequately controlled with monotherapy or dual therapy.\n\nManagement of fasting and postprandial hyperglycemia.\n\nLong-term HbA1c reduction as part of a comprehensive diabetes care plan.\n\n \n\nKey Benefits\n✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels.\n✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges.\n✅ Reduced Pill Burden – Combines three medicines into a single tablet.\n✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect.\n✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain.\n✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort.\n\n \n\nDosage and Administration\nRecommended dose: One tablet once or twice daily with meals, or as directed by the physician.\n\nAdministration tips:\n\nTake with the first bite of a main meal to maximize Voglibose’s effect.\n\nSwallow whole with water; do not crush or chew the SR tablet.\n\nDose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function.\n\n \n\nContraindications\nGLIMITERIS MV1 0.2 is not suitable for patients with:\n\nType 1 diabetes or diabetic ketoacidosis.\n\nSevere renal impairment (eGFR <30 mL/min/1.73 m²).\n\nHepatic dysfunction.\n\nSevere gastrointestinal diseases.\n\nHistory of lactic acidosis.\n\nHypersensitivity to Glimepiride, Voglibose, or Metformin.\n\nPregnancy and lactation (unless strictly advised by a physician).\n\n \n\nWarnings and Precautions\nHypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals.\n\nLactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential.\n\nGI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary).\n\nVitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption.\n\nLiver and Kidney Function: Regular monitoring is recommended for safe long-term use.\n\n \n\nAdverse Effects\nCommon:\nGlimepiride: Mild hypoglycemia, dizziness, slight weight gain.\n\nVoglibose: Gas, abdominal discomfort, mild diarrhea.\n\nMetformin SR: Nausea, bloating, metallic taste, loose stools.\n\nRare but Serious:\nLactic acidosis (from Metformin).\n\nSevere hypoglycemia (especially if meals are skipped).\n\nAllergic reactions such as rash, itching, or swelling.\n\nElevated liver enzymes.\n\nSeek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur.\n\n \n\nDrug Interactions\nIncreased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas.\n\nReduced Metformin efficacy: With corticosteroids, estrogens, and diuretics.\n\nLactic acidosis risk: Higher with alcohol or iodinated contrast agents. ", "price": 263.0, "discountamount": 80.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2182, "imageuri": "https://productimages.withfloats.com/actual/68d51d9cdf1a4ca2c252370a.png", "tileimageuri": "https://productimages.withfloats.com/tile/68d51d9cdf1a4ca2c252370a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-25T10:46:50.098Z", "updatedon": "2025-09-25T10:46:50.098Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-ip1-mg-voglibose-ip-0-2-mg-metformin-hydrochloride-ip-500-mg-/2182", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS MV1 0.2", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6825c6cc966e2a18bb4b35a6", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA PIO", "description": "GLIDAPA PIO is a combination oral medication specially formulated to help manage type 2 diabetes mellitus. It combines two powerful antidiabetic agents, dapagliflozin and pioglitazone, to effectively control blood sugar levels. This medication is prescribed to patients when diet and exercise alone do not provide adequate glycemic control. By addressing blood glucose regulation through different mechanisms, GLIDAPA PIO helps reduce the risk of diabetes-related complications and supports overall metabolic health.\n\nKey Ingredients\nDapagliflozin (10mg): A sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by increasing the excretion of glucose through urine.\n\nPioglitazone (15mg): A thiazolidinedione that improves insulin sensitivity by acting on fat, muscle, and liver cells, facilitating better glucose uptake and utilization.\n\nKey Benefits\nHelps maintain stable blood glucose levels in adults with type 2 diabetes.\n\nCombines two complementary mechanisms to enhance blood sugar control.\n\nSupports weight management due to dapagliflozin’s glucose excretion effect.\n\nMay improve insulin sensitivity and reduce insulin resistance.\n\nReduces the risk of diabetes-related complications such as cardiovascular problems when combined with lifestyle changes.\n\nConvenient once-daily tablet formulation.\n\nHow Does It Work?\nDapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting its elimination through urine, which lowers blood glucose. Pioglitazone acts on insulin-responsive tissues, enhancing the body’s sensitivity to insulin. This dual action helps reduce both insulin resistance and excess blood glucose, providing better overall glycemic control. By targeting different pathways, GLIDAPA PIO offers a synergistic effect to manage type 2 diabetes more effectively.\n\nDirections for Use\nTake GLIDAPA PIO exactly as prescribed by your healthcare provider.\n\nUsually taken once daily, with or without food, at the same time each day.\n\nDo not skip doses or stop the medication without consulting your doctor.\n\nMaintain a balanced diet and regular exercise as advised alongside the medication.\n\nInform your doctor about any other medications you are taking to avoid potential interactions.\n\nSide Effects\nSome patients may experience side effects while taking GLIDAPA PIO, including:\n\nUrinary tract infections or increased urination due to dapagliflozin.\n\nWeight gain or swelling caused by pioglitazone.\n\nRisk of low blood sugar (hypoglycemia) when combined with other antidiabetic drugs.\n\nPossible dizziness or fatigue.\n\nRarely, heart failure or bladder cancer risk (associated with pioglitazone).\n\nIf you notice symptoms like excessive thirst, sudden weight gain, swelling, shortness of breath, or any allergic reactions, seek medical advice immediately.", "price": 255.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medication inform", "pioglitazone risk", "regular exercise", "balanced diet", "doctor maintain", "glucose uptake", "notice symptoms", "antidiabetic drugs", "swelling caused", "advised alongside", "skip doses", "healthcare provider", "effectively directions", "synergistic effect", "glycemic control", "cardiovascular problems", "complementary mechanisms", "fat muscle", "diabetesrelated complications", "insulin resistance", "bodys sensitivity", "glidapa pio", "urine pioglitazone 15mg", "taking glidapa pio", "bladder cancer risk", "improve insulin sensitivity", "improves insulin sensitivity", "glidapa pioglidapa pio", "dapagliflozin weight gain", "increased urination due", "urinary tract infections", "experience side effects", "insulinresponsive tissues enhancing", "liver cells facilitating" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2114, "imageuri": "https://productimages.withfloats.com/actual/6825c6ce65488af627fb2e46.png", "tileimageuri": "https://productimages.withfloats.com/tile/6825c6ce65488af627fb2e46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-15T10:49:48.361Z", "updatedon": "2025-05-15T10:50:30.602Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-pio/2114", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Dapagliflozin 10mg and pioglitazone 15mg tablets", "category": "DIABETIC RANGE", "tags": [ "Dapagliflozin, pioglitazone combination", "Dapagliflozin, pioglitazone combination", "Dapagliflozin Pioglitazone CDSCO" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6819f2b5b631af66ff847b24", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ORAVERSE M", "description": "ORAVERSE M is a meticulously formulated health supplement combining Myo-inositol (600 mg) with Metformin Hydrochloride (500 mg), specifically developed to boost metabolic wellness, particularly for those affected by polycystic ovary syndrome (PCOS) and insulin resistance. This dual-component preparation addresses hormonal equilibrium, glucose utilization, and ovarian health, providing a thorough solution for enhancing reproductive and metabolic functioning. Healthcare professionals frequently recommend it as part of treatment strategies for women with PCOS or individuals struggling with insulin sensitivity and irregular ovulation patterns.\nEssential Components:\n\nMyo-inositol IP (600 mg): A nutrient resembling vitamins (within the B-complex family), Myo-inositol serves a crucial function in cellular communication, particularly insulin signal transmission. It's recognized for its positive influence on ovarian activity, hormone regulation, and metabolic function.\nMetformin Hydrochloride (500 mg): A proven anti-diabetic medicine that helps reduce blood sugar and enhance insulin effectiveness. It's widely prescribed for Type 2 diabetes mellitus and PCOS-related insulin resistance.\n\nPrimary Advantages:\n\nBoosts Insulin Response: Both Myo-inositol and Metformin function complementarily to improve insulin sensitivity and reduce resistance, a key factor in metabolic disorders and PCOS.\nRegulates Menstrual Cycles & Ovulation: Particularly valuable for PCOS patients, ORAVERSE M may help normalize menstrual patterns and encourage ovulation.\nSupports Ovarian Health: Myo-inositol aids follicular development and egg quality, potentially enhancing fertility prospects.\nAlleviates High Androgen Symptoms: Helps manage manifestations like acne, excessive body hair, and hair thinning caused by elevated male hormone levels in PCOS.\nSupports Weight Management: Enhances metabolic factors that contribute to better weight control, especially for those with insulin resistance.\nReduces Diabetes Risk: By improving blood sugar regulation and lowering insulin levels, this formulation may help prevent progression to diabetes.\n\nFunctional Mechanism:\nORAVERSE M operates through a complementary action:\n\nMyo-inositol enhances insulin signaling at the cellular level, supporting glucose uptake and metabolism. It also influences luteinizing hormone (LH) and follicle-stimulating hormone (FSH) regulation, helping restore hormonal balance critical in PCOS.\nMetformin Hydrochloride decreases liver glucose production and increases insulin sensitivity in muscle and fat tissues, resulting in improved blood sugar control. For women with PCOS, Metformin also helps normalize menstrual cycles and ovulation.\n\nTogether, these ingredients help restore metabolic and reproductive wellness by addressing the root causes of PCOS and related metabolic disruptions.\nUsage Guidelines:\n\nStandard Dosage: One ORAVERSE M tablet is typically taken once or twice daily, as recommended by a physician.\nAdministration Method: Take with meals to minimize digestive discomfort. Swallow whole with water—avoid crushing or chewing.\nImportant: Always follow your healthcare provider's specific instructions regarding dosage and treatment duration.\n\nPotential Side Effects:\nORAVERSE M is generally well-tolerated, though some users may experience effects, particularly when beginning treatment:\n\nCommon Reactions:\n\nNausea\nBloating or gas\nMild diarrhea\nStomach discomfort\nMetallic taste (Metformin-related)\n\n\nLess Common but Significant:\n\nVitamin B12 deficiency (with prolonged Metformin use)\nMild dizziness or headache\nLow blood sugar (uncommon, especially when combined with other diabetes medications)", "price": 275.0, "discountamount": 83.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "diabetes medications", "mild dizziness", "experience effects", "generally welltolerated", "chewing important", "wateravoid crushing", "prevent progression", "weight control", "key factor", "reduce resistance", "widely prescribed", "positive influence", "cellular communication", "individuals struggling", "treatment strategies", "enhancing reproductive", "oraverse moraverse", "pcos metformin", "prolonged metformin", "restore metabolic", "metabolic disorders", "reproductive wellness", "crucial function", "insulin resistance", "insulin sensitivity", "pcos patients oraverse", "metformin function complementarily", "boost metabolic wellness", "increases insulin sensitivity", "improve insulin sensitivity", "lowering insulin levels", "enhance insulin effectiveness", "insulin signal transmission", "physician administration method", "fat tissues resulting", "hair thinning caused", "normalize menstrual patterns", "proven antidiabetic medicine", "nutrient resembling vitamins", "ovarian health providing" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2102, "imageuri": "https://productimages.withfloats.com/actual/6819f2b79d6e117a7e9250d7.png", "tileimageuri": "https://productimages.withfloats.com/tile/6819f2b79d6e117a7e9250d7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-06T11:29:57.58Z", "updatedon": "2025-05-06T11:29:57.58Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/oraverse-m/2102", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Myo-inositol IP (600 mg), Metformin Hydrochloride (500 mg)", "category": "Gynaecology", "tags": [ "myo-inositol 600 mg & metformin hydrochloride 500 mg (sustained release) tablets", "Myo-Inositol 600 mg and Metformin hydrochloride 500 mg Uses in Hindi", "myo-inositol 600 mg & metformin hydrochloride 500 mg uses", "myo-inositol 600 mg & metformin hydrochloride 500 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6810aa8d5a26e4010ea41a99", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH MET", "description": "EMPATECH MET 12.5/500 is a powerful oral antidiabetic combination therapy containing Empagliflozin and Metformin Hydrochloride, designed to manage Type 2 Diabetes Mellitus effectively. This dual-action formula helps control blood sugar levels, supports weight management, and offers added cardiovascular benefits. EMPATECH MET 12.5/500 is particularly beneficial for adults who require a second-line treatment when diet, exercise, and monotherapy are not sufficient.\n\nKey Ingredients\nEmpagliflozin (12.5 mg):\nA sodium-glucose co-transporter-2 (SGLT2) inhibitor that helps reduce blood glucose levels by promoting glucose excretion through urine.\n\nMetformin Hydrochloride (500 mg):\nA biguanide class medication that lowers blood glucose by improving insulin sensitivity and reducing glucose production in the liver.\n\nKey Benefits\nHelps in lowering and maintaining stable blood glucose levels\n\nPromotes weight loss and reduces visceral fat\n\nReduces the risk of cardiovascular complications in diabetic patients\n\nSupports renal protection in people with diabetes and mild kidney dysfunction\n\nOffers a low risk of hypoglycemia compared to some other therapies\n\nImproves glycemic control with a dual mechanism of action\n\nHow Does It Work?\nEMPATECH MET 12.5/500 functions through two complementary mechanisms:\n\nEmpagliflozin works by blocking SGLT2 proteins in the kidneys, reducing the reabsorption of glucose and increasing its excretion via urine. This lowers blood sugar levels independently of insulin action.\n\nMetformin acts primarily by inhibiting hepatic glucose production and improving the body’s sensitivity to insulin, allowing for better uptake and usage of glucose by muscles and fat tissues.\n\nTogether, they provide a comprehensive glycemic control strategy, especially for patients not responding well to monotherapy.\n\nDirections for Use\nTake the tablet as prescribed by your doctor, usually once or twice daily with meals.\n\nSwallow the tablet whole with water; do not crush or chew.\n\nContinue following a healthy diet and regular exercise routine for optimal results.\n\nMonitor blood sugar levels regularly and report any unusual changes to your healthcare provider.\n\nDo not stop the medication without medical advice, even if your blood sugar levels improve.\n\nSide Effects\nCommon Side Effects:\n\nIncreased urination\n\nThirst or dry mouth\n\nNausea or mild gastrointestinal upset\n\nHeadache\n\nFatigue\n\nLess Common but Serious Side Effects:\n\nRisk of urinary tract infections or genital infections\n\nLactic acidosis (rare but serious; associated with Metformin)\n\nDehydration or low blood pressure, especially in elderly patients\n\nElectrolyte imbalances\n\nSeek immediate medical help if you experience severe abdominal pain, muscle cramping, breathing difficulties, or unusual tiredness.", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "unusual tiredness", "medical advice", "monotherapy directions", "healthcare provider", "healthy diet", "chew continue", "meals swallow", "fat tissues", "dual mechanism", "hypoglycemia compared", "cardiovascular complications", "secondline treatment", "metformin dehydration", "insulin allowing", "bodys sensitivity", "kidneys reducing", "low risk", "diet exercise", "improving insulin sensitivity", "promoting glucose excretion", "reducing glucose production", "side effects risk", "biguanide class medication", "lowers blood glucose", "low blood pressure", "regular exercise routine", "metformin hydrochloride designed", "urinary tract infections", "dry mouth nausea", "blocking sglt2 proteins" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2093, "imageuri": "https://productimages.withfloats.com/actual/6810aa8f5c4a4ba3d41a8c35.png", "tileimageuri": "https://productimages.withfloats.com/tile/6810aa8f5c4a4ba3d41a8c35.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-04-29T10:31:41.504Z", "updatedon": "2025-04-29T10:32:46.171Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-met/2093", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin (12.5mg) ,Metformin Hydrochloride (500mg)", "category": "DIABETIC RANGE", "tags": [ "empagliflozin 12.5 mg+metformin 500 mg price", "empagliflozin 12.5 mg+metformin 1000 mg", "empagliflozin 12.5mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "674b0a7ee34075b8291b14f1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride 0.5 mg, Voglibose 0.2 mg & Metformin Hydrochloride (SR) 500 mg Tablets", "description": "Diabetes management often requires a multifaceted approach to address the complexities of glucose regulation. Glimiteris Trio 0.5/0.2/500 offers a synergistic combination of three proven antidiabetic agents. This tablet not only targets fasting and postprandial blood glucose but also improves the body’s insulin utilization, ensuring better glycemic control and reducing the risk of complications associated with diabetes.\n\n \nKey Benefits:\nEffective Blood Sugar Management: Works on multiple pathways to control both fasting and postprandial blood glucose levels.\nReduces Insulin Resistance: Enhances the body's response to insulin, improving its efficacy.\nMinimizes Post-Meal Glucose Spikes: Voglibose slows carbohydrate digestion and absorption, keeping postprandial glucose in check.\nImproves Long-Term Glycemic Control: Helps in achieving and maintaining stable HbA1c levels.\nSustained Release Formula: Metformin’s SR formulation ensures prolonged action, reducing the need for frequent dosing.\nComprehensive Diabetes Management: Prevents complications like neuropathy, retinopathy, and cardiovascular issues associated with diabetes.\nHow Does It Work?\nGlimepiride: Stimulates the pancreas to release insulin, directly lowering blood glucose levels.\nVoglibose: Inhibits enzymes that break down carbohydrates into glucose, thereby delaying glucose absorption and controlling post-meal spikes.\nMetformin Hydrochloride SR: Decreases hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity, ensuring balanced glucose levels throughout the day.\nTogether, these three ingredients address the multifaceted nature of type 2 diabetes, providing a holistic solution for effective blood sugar control.\n\nDirections for Use:\nDosage: Take one tablet as prescribed by your healthcare professional, usually once or twice daily with meals.\nSwallow Whole: Do not crush or chew the tablet; it is designed for sustained release.\nTiming: Preferably consume with a meal to reduce gastrointestinal discomfort and optimize efficacy.\nFollow Medical Advice: Stick to the prescribed dosage and schedule for optimal results.\nAlways consult your doctor before starting or adjusting your dosage.\n\nSide Effects:\nWhile Glimiteris Trio 0.5/0.2/500 is generally well-tolerated, some individuals may experience side effects, including:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nStomach discomfort or flatulence\nMild hypoglycemia (low blood sugar levels)\nRare but Serious Side Effects:\n\nSevere hypoglycemia\nLactic acidosis (from Metformin)\nAllergic reactions such as rash or itching\n\n", "price": 153.0, "discountamount": 46.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "prescribed dosage", "ingredients address", "glycemic control", "targets fasting", "generally welltolerated", "glimiteris trio 0502500", "optimal results", "meals swallow", "healthcare professional", "holistic solution", "multifaceted nature", "cardiovascular issues", "neuropathy retinopathy", "insulin improving", "bodys response", "multiple pathways", "synergistic combination", "multifaceted approach", "dosage side effects", "delaying glucose absorption", "postprandial blood glucose", "metformin allergic reactions", "diarrhea stomach discomfort", "experience side effects", "reduce gastrointestinal discomfort", "work glimepiride stimulates", "proven antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2016, "imageuri": "https://productimages.withfloats.com/actual/674b0a80ec7bb8b7dcae8a8a.png", "tileimageuri": "https://productimages.withfloats.com/tile/674b0a80ec7bb8b7dcae8a8a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-11-30T12:52:14.799Z", "updatedon": "2024-11-30T12:52:14.799Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-0-5-mg-voglibose-0-2-mg-metformin-hydrochloride-sr-500-mg-tablets/2016", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS TRIO 0.5/0.2/500 ", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67122bef263d0316fb4c9dcb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gliclazide IP (40 mg) , Pioglitazone Hydrochloride IP (15 mg) , Metformin Hydrochloride IP (500 mg)", "description": "TRI-GLICLAGLAZE 40 is a powerful oral anti-diabetic medication formulated to manage Type 2 Diabetes Mellitus effectively. This combination of three potent drugs—Gliclazide, Pioglitazone, and Metformin—works synergistically to control high blood sugar levels, improve insulin sensitivity, and help patients achieve better glycemic control. TRI-GLICLAGLAZE 40 is designed for patients who struggle to manage blood glucose levels with single medications or lifestyle changes alone. It is a comprehensive solution for long-term diabetes management and reducing the risk of complications related to uncontrolled blood sugar.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: TRI-GLICLAGLAZE 40 helps maintain optimal blood glucose levels by targeting different aspects of diabetes management, such as stimulating insulin release, improving insulin sensitivity, and reducing glucose production.\nReduces Insulin Resistance: Pioglitazone and Metformin work together to lower insulin resistance, making it easier for the body to use insulin effectively.\nImproves Long-Term Glycemic Control: By combining three active ingredients, this medication is particularly beneficial for those struggling with glycemic control through diet or monotherapy alone.\nReduces Risk of Diabetes Complications: Controlling blood sugar levels helps prevent diabetes-related complications such as nerve damage, kidney disease, and cardiovascular problems.\nSupports Weight Management: Metformin, in particular, has been known to assist with weight management, which is important for patients with Type 2 Diabetes.\n \n\nHow Does It Work?\n \nTRI-GLICLAGLAZE 40 works through a multi-faceted mechanism to lower blood glucose levels:\n\nGliclazide stimulates the beta cells in the pancreas to release more insulin, which lowers blood sugar levels post-meal.\n\nPioglitazone enhances the body's sensitivity to insulin by promoting glucose uptake in the muscle and fat cells while also decreasing glucose production in the liver.\n\nMetformin reduces the production of glucose in the liver and improves insulin sensitivity. It also decreases the absorption of sugar from the intestines, ensuring better blood sugar control throughout the day.\n\nThis combination of ingredients targets multiple pathways involved in glucose regulation, making it an effective option for individuals with Type 2 Diabetes who require more comprehensive blood sugar control.\n\n \n\nDirections for Use:\n \nTake TRI-GLICLAGLAZE 40 exactly as prescribed by your doctor.\nUsually, it is taken once or twice daily with meals to minimize gastrointestinal discomfort.\nSwallow the tablet whole with water—do not crush or chew the tablet.\nContinue following your diet and exercise plan alongside the medication to achieve optimal blood sugar control.\nDo not skip doses, and consult your healthcare provider if you miss a dose.\n \n\nSide Effects:\n \nLike any medication, TRI-GLICLAGLAZE 40 may cause side effects, although not everyone experiences them. Some common and mild side effects include:\n\nHypoglycemia (Low Blood Sugar): Due to Gliclazide’s insulin-stimulating properties, low blood sugar may occur, especially if meals are skipped or exercise is excessive.\n\nGastrointestinal Issues: Metformin is known to cause digestive problems in some individuals, including nausea, vomiting, diarrhea, or stomach cramps.\n\nWeight Gain: Pioglitazone may cause weight gain in some users due to increased fat storage.\n\nFluid Retention: Pioglitazone may lead to water retention, especially in patients with heart conditions, increasing the risk of heart failure.\n\nHeadache and dizziness: These may occur as the body adjusts to the medication, but they are generally mild and temporary.\n\nLactic Acidosis (rare): A serious but rare side effect of Metformin, this condition requires immediate medical attention and is characterized by muscle pain, breathing difficulties, and weakness.\n\n ", "price": 145.0, "discountamount": 43.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "fat cells", "beta cells", "muscle pain", "fat storage", "Weight Gain", "nerve damage", "Key Benefits", "exercise plan", "Gliclazide IP", "heart failure", "stomach cramps", "kidney disease", "glucose uptake", "water retention", "insulin release", "Lactic Acidosis", "Fluid Retention", "Low Blood Sugar", "heart conditions", "rare side effect", "multiple pathways", "different aspects", "lifestyle changes", "Weight Management", "mild side effects", "Insulin Resistance", "digestive problems", "single medications", "glucose production", "glucose regulation", "three potent drugs", "insulin sensitivity", "healthcare provider", "breathing difficulties", "Diabetes Complications", "comprehensive solution", "Metformin Hydrochloride", "Gastrointestinal Issues", "multi-faceted mechanism", "cardiovascular problems", "high blood sugar levels", "Type 2 Diabetes Mellitus", "three active ingredients", "uncontrolled blood sugar", "Long-Term Glycemic Control", "gastrointestinal discomfort", "immediate medical attention", "optimal blood sugar control", "optimal blood glucose levels", "Pioglitazone Hydrochloride IP", "long-term diabetes management", "Effective Blood Sugar Control", "diabetes-related complications", "insulin-stimulating properties", "comprehensive blood sugar control", "powerful oral anti-diabetic medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1994, "imageuri": "https://productimages.withfloats.com/actual/67122bf4ac30f07ce03345d7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67122bf4ac30f07ce03345d7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-10-18T09:35:43.008Z", "updatedon": "2024-10-18T09:35:43.008Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclazide-ip-40-mg-pioglitazone-hydrochloride-ip-15-mg-metformin-hydrochloride-ip-500-mg-/1994", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRI - GLICLAGLAZE 40 ", "category": "DIABETIC RANGE", "tags": [ "gliclazide+metformin hydrochloride tablets uses", "Gliclazide Metformin Pioglitazone brand name", "Gliclazide and Metformin hydrochloride tablets Use", "Gliclazide and Metformin Hydrochloride tablets pri", "Gliclazide and Metformin Hydrochloride Tablets bra", "Gliclazide 80 mg and Metformin Hydrochloride table", "", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "66d83ad4ed345980e0fca5c5", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Voglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)", "description": "GLICLAGLAZE TRIO 0.3 \nVoglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)\nGLICLAGLAZE TRIO 0.3 is a powerful combination medication designed to manage and control type 2 diabetes. It is formulated with three active ingredients: Voglibose, Metformin, and Gliclazide. This unique combination helps to regulate blood sugar levels effectively, providing a comprehensive approach to diabetes management. GLICLAGLAZE TRIO 0.3 is particularly useful for patients who require a multifaceted treatment strategy to keep their blood glucose levels in check.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: The combination of Voglibose, Metformin, and Gliclazide offers a synergistic effect, providing comprehensive control over blood sugar levels.\nPrevents Post-Meal Sugar Spikes: Voglibose helps in delaying glucose absorption, reducing the risk of hyperglycemia after meals.\nImproved Insulin Sensitivity: Metformin enhances the body's response to insulin, ensuring better glucose management.\nEnhanced Insulin Secretion: Gliclazide helps in stimulating insulin release from the pancreas, making it easier to maintain stable blood sugar levels.\n \n\nHow Does It Work?\n \n\nGLICLAGLAZE TRIO 0.3 works through a multi-pronged approach to manage diabetes. Voglibose slows down the absorption of carbohydrates in the gut, which helps to prevent rapid increases in blood sugar levels after meals. Metformin reduces the liver's glucose production and improves insulin sensitivity, ensuring better glucose uptake and utilization. Gliclazide stimulates the pancreas to release insulin, aiding in the reduction of blood glucose levels.\n\n \n\nDirections for Use:\n \n\nTake GLICLAGLAZE TRIO 0.3 as prescribed by your healthcare provider. It is typically taken before meals to maximize its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Your doctor will determine the appropriate dosage and frequency based on your individual health needs.\n\n \n\nSide Effects:\n \n\nLike all medications, GLICLAGLAZE TRIO 0.3 may cause some side effects. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Hypoglycemia (low blood sugar) may occur, especially if you skip meals or engage in intense physical activity. Other possible side effects include dizziness, headache, and fatigue. If you experience any severe side effects or allergic reactions, seek medical attention immediately.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 185.0, "discountamount": 56.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Key Benefits", "abdominal pain", "glucose uptake", "type 2 diabetes", "rapid increases", "insulin release", "low blood sugar", "GLICLAGLAZE TRIO", "medical attention", "glucose absorption", "allergic reactions", "appropriate dosage", "synergistic effect", "unique combination", "glucose production", "glucose management", "diabetes management", "healthcare provider", "severe side effects", "Common side effects", "blood glucose levels", "comprehensive control", "multi-pronged approach", "comprehensive approach", "Post-Meal Sugar Spikes", "individual health needs", "three active ingredients", "intense physical activity", "stable blood sugar levels", "Enhanced Insulin Secretion", "Other possible side effects", "Improved Insulin Sensitivity", "gastrointestinal disturbances", "Effective Blood Sugar Control", "powerful combination medication", "multifaceted treatment strategy", "postprandial blood sugar spikes" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1962, "imageuri": "https://productimages.withfloats.com/actual/66d83afac7293b3595ec4ea6.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/66d83afac7293b3595ec4ea6.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-04T10:47:48.369Z", "updatedon": "2024-09-04T10:47:48.369Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/voglibose-0-3mg-metformin-500mg-gliclazide-80mg-/1962", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }